Browse studies

Find your next paid study

6 recruiting studies matching your filters

Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study

Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, whic…

Lymphohistiocytosis, HemophagocyticSecondary Hemophagocytic LymphohistiocytosisMacrophage Activation Syndrome+1 more

Estimated

~$10 – $675

National Institute of Allergy and Infectious Diseases (NIAID)NCT06339177

Phase 1

Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)

This is a pilot study to gather information about safety and efficacy of using ruxolitinib (RUX) to treat Immune Effector Cell Associated Hemophagocytic Lympho…

Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)

Estimated

~$10 – $6,250

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07424222

Phase 1

Pilot Study of Pre-emptive Anakinra for the Prevention of Severe Cytokine Release Syndrome in Children and Young Adults With B-Acute Lymphoblastic Leukemia Receiving Chimeric Antigen Receptor (CAR) T Cells

Objectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (…

B-Acute Lymphoblastic LeukemiaCAR-T Cell TherapyCytokine Release Syndrome+2 more

Estimated

~$10 – $7,500

Kevin McNerneyNCT06703216

Phase 2

A Phase II Prospective Study Evaluating Selective Depletion of CD45RA+ (Naïve) T Cells (TND) From Peripheral Blood Stem Cell (PBSC) Grafts for Prevention of Graft Versus Host Disease (GVHD) in Non-Malignant Diseases (NMDs)

This phase II trial investigates how well a naive T cell depleted graft work for the reduction of graft versus host disease in patients with non-malignant dise…

Bone Marrow FailureHemoglobinopathiesPrimary Immune Deficiency (PID)+4 more

Estimated

~$10 – $6,250

Fred Hutchinson Cancer CenterNCT07660783

Phase 2

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocyt…

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Estimated

~$10 – $8,750

Electra Therapeutics Inc.NCT05416307

Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, …

Rare DisordersUndiagnosed DisordersDisorders of Unknown Prevalence+340 more